Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

HRMY

Strong BuyAPPROVE

Harmony Biosciences Holdings, Inc. · Healthcare · United States · $2.3B · Avg Vol: $31M/d

100
StockRank
Get insider-trade alerts
Q
82
V
72
M
88
P/E (TTM)
12.6x
ROE
20.5%
D/E
0.2x
Dividend %
—
Dir. Trades · 180d
None →
Buybacks · 180d
None →
AI CONVICTION THESIS

Harmony Biosciences is executing as a high-ROIC innovator with a best-in-class profile for its Orexin-2 agonist, BP-205. The management team has demonstrated exceptional capital allocation, and the 11.1% consensus EPS upward revision reflects strong fundamental growth decoupled from broader macro noise.

COMPANY DESCRIPTION

Harmony Biosciences Holdings, Inc. is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients suffering from rare neurological diseases. With its flagship product WAKIX for narcolepsy already commercialized, the company establishes a strong market position by addressing significant unmet medical needs within niche neurological disorder markets.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue437.9M582.0M714.7M868.5M25.6%959.9M1.0B1.2B15.8%
EPS3.072.172.562.76-3.5%3.154.005.1336.3%
Shares59.6M56.8M57.1M57.7M-3.2%58.2M———
Debt191.6M193.6M179.3M163.7M-5.1%160.2M———
Equity402.8M467.0M659.2M870.2M29.3%————
Op CF144.5M219.4M219.8M348.2M34.1%355.1M———
Inv CF-141.8M-46.4M-67.5M-39.6M—————
Fin CF6.8M-105.6M-11.0M-9.0M—————
Loading 1Y...
PRICE (1Y)+19.7%
35.2437.1539.0540.9642.86Jul 23Aug 13Sep 2
SMA 50SMA 200

Close
$42.86
RSI (14)
71.5
52W High
$43.02
From 52W High
1.0%

SCORE BREAKDOWN

Quality
82
ROIC
25.0%94.9
ROE
20.5%89.3
GP/Assets
56.9%90.3
Op. Margin
34.2%94.1
FCF/Assets
27.4%98.0
Piotroski
550.7
Int. Cover
18.9x71.4
D/E Ratio
0.16x54.2
Current Ratio
3.48x59.3
Value
72
P/E (TTM)
12.6x80.8
EV/EBITDA
6.9x83.9
P/FCF
6.6x89.3
P/B
2.3x55.5
P/S
2.4x63.1
Div Yield
—N/A
Momentum
88
52W High %
100%99.2
RS 6M
38%88.6
SMA 50/200
1.09x76.1
EPS Rev 4W
+11.1%90.0
EPS Rev 12W
+19.8%92.1
EPS Improve
+112%77.3
Q Growth
90%82.1

FUNDAMENTALS

Market Cap
$2.3B
P/E (Forward)
5.9x
Gross Margin
75.4%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HRMY are excluded.

TickerCompanyMkt CapStockRankSignal
HRMYHarmony Biosciences Holdings, Inc.(you)$2.3B100Strong Buy
INVAInnoviva, Inc.$1.5B93Strong Buy
RIGLRigel Pharmaceuticals, Inc.$868M99Strong Buy
CRMDCorMedix Inc.$647M98Strong Buy
PBYIPuma Biotechnology, Inc.$468M98Strong Buy
ABUSArbutus Biopharma Corporation$1.0B83Strong Buy
ACADACADIA Pharmaceuticals Inc.$5.0B82Strong Buy
FTREFortrea Holdings Inc.$1.8B70Buy
ZVRAZevra Therapeutics, Inc.$687M89Strong Buy
EXELExelixis, Inc.$13.5B99Strong Buy

Peer medians: ROE -30.8% · P/E 27.6x · Gross margin 58.3%

Harmony Biosciences Holdings, Inc. (HRMY): Stock Score Summary

Harmony Biosciences Holdings, Inc. (HRMY) has a MoatMap StockRank of 100/100 based on Quality (82/100), Value (72/100), and Momentum (88/100) factor scores. The current signal is STRONG BUY. Harmony Biosciences is executing as a high-ROIC innovator with a best-in-class profile for its Orexin-2 agonist, BP-205. The management team has demonstrated exceptional capital allocation, and the 11.1% consensus EPS upward revision reflects strong fundamental growth decoupled from broader macro noise.

Harmony Biosciences Holdings, Inc. is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients suffering from rare neurological diseases. With its flagship product WAKIX for narcolepsy already commercialized, the company establishes a strong market position by addressing significant unmet medical needs within niche neurological disorder markets.

Key Financial Metrics

Price$42.86
Market Cap$2.3B
P/E (TTM)12.59
P/E (Forward)5.93
Price/Book2.31
Return on Equity20.5%
Return on Invested Capital25.0%
Debt/Equity0.16x
Gross Margin75.4%
Operating Margin34.2%
Revenue Growth30.3%
Free Cash Flow$348M

Harmony Biosciences Holdings, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Harmony Biosciences Holdings, Inc.’s (HRMY) StockRank?
MoatMap’s StockRank for Harmony Biosciences Holdings, Inc. (HRMY) is 100/100, with a Strong Buy signal. It is a composite of Quality (82), Value (72), and Momentum (88) factor ranks across MoatMap’s 20,000+ stock universe.
Does Harmony Biosciences Holdings, Inc. have an economic moat?
Harmony Biosciences Holdings, Inc. (HRMY) has a Quality factor score of 82/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Harmony Biosciences Holdings, Inc. a buy, hold, or sell?
MoatMap’s current signal for Harmony Biosciences Holdings, Inc. (HRMY) is Strong Buy, based on a StockRank of 100/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Harmony Biosciences Holdings, Inc. in?
Harmony Biosciences Holdings, Inc. (HRMY) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksHRMY deep dive reportAI ChampionsHow we score stocksSense-check another stock